Top 100 Contractors in NAICS 325412: Pharmaceutical Preparation Manufacturing, FY2022

Parent companies by net contract obligations Oct 1, 2021 – Sep 30, 2022 Code page on GovTribe

The top 10 won 95% of FY2022 NAICS 325412 contract dollars

Ranking facts

Contract obligations
$34,850,249,877 Net of deobligations, by contracts coded NAICS 325412
Contractors
330 Parent companies with an obligation
Largest contractor
Pfizer Inc. $14.6 billion, 41.5% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 100 rows as CSV

Full ranking

Rank Contractor Net obligations Share Trend
1 $14,631,541,299
Rank history: #44 in FY2021, #2 in FY2023, not on the FY2024 list and #48 in FY2025; up 43 since FY2021.
2 $9,760,229,976
Rank history: #1 in FY2021, #1 in FY2023, #1 in FY2024 and #1 in FY2025; down 1 since FY2021.
3 $2,752,650,080
Rank history: #3 in FY2021 and not on the FY2023–FY2025 lists; unchanged since FY2021.
4
Modernatx Inc. 2 awardees, including Moderna US, Inc.
$1,847,427,026
Rank history: #2 in FY2021 and not on the FY2023–FY2025 lists; down 2 since FY2021.
5 $1,637,211,649
Rank history: #5 in FY2021, #43 in FY2023, #31 in FY2024 and #23 in FY2025; unchanged since FY2021.
6 $997,232,941
Rank history: #4 in FY2021 and not on the FY2023–FY2025 lists; down 2 since FY2021.
7 $605,472,889
Rank history: #9 in FY2021 and not on the FY2023–FY2025 lists; up 2 since FY2021.
8 $575,986,653
Rank history: #7 in FY2021 and not on the FY2023–FY2025 lists; down 1 since FY2021.
9 $400,459,258
Rank history: #13 in FY2021, #20 in FY2023 and not on the FY2024–FY2025 lists; up 4 since FY2021.
10 $384,184,925
Rank history: #6 in FY2021 and not on the FY2023–FY2025 lists; down 4 since FY2021.
11 $293,125,000
Rank history: #8 in FY2021, #5 in FY2023, #3 in FY2024 and #3 in FY2025; down 3 since FY2021.
12 $139,676,048
Rank history: not on the FY2021 list, #22 in FY2023, not on the FY2024 list and #4 in FY2025; new.
13 $87,000,000
Rank history: not on the FY2021 list, #8 in FY2023, #6 in FY2024 and #26 in FY2025; new.
14 $77,980,000
Rank history: #16 in FY2021, #7 in FY2023, #7 in FY2024 and #6 in FY2025; up 2 since FY2021.
15 $74,085,391
Rank history: #10 in FY2021, #4 in FY2023 and not on the FY2024–FY2025 lists; down 5 since FY2021.
16 $59,026,988
Rank history: not on the FY2021 list, #14 in FY2023, #18 in FY2024 and #13 in FY2025; new.
17
Sagent Pharmaceuticals Inc.
$47,750,652
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
18 $37,941,480
Rank history: #28 in FY2021 and not on the FY2023–FY2025 lists; up 10 since FY2021.
19 $35,249,148
Rank history: #19 in FY2021, #51 in FY2023, #85 in FY2024 and not on the FY2025 list; unchanged since FY2021.
20
Teva Pharmaceutical Industries Ltd. Through Teva Pharmaceuticals Usa, Inc.
$35,215,784
Rank history: #18 in FY2021, #9 in FY2023, #28 in FY2024 and not on the FY2025 list; down 2 since FY2021.
21 $30,569,868
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 90 since FY2021.
22 $30,135,185
Rank history: #15 in FY2021 and not on the FY2023–FY2025 lists; down 7 since FY2021.
23 $25,521,675
Rank history: #20 in FY2021, #17 in FY2023, #19 in FY2024 and not on the FY2025 list; down 3 since FY2021.
24 $23,533,768
Rank history: #23 in FY2021, #11 in FY2023, #16 in FY2024 and #15 in FY2025; down 1 since FY2021.
25 $18,976,439
Rank history: #95 in FY2021, #10 in FY2023, #40 in FY2024 and not on the FY2025 list; up 70 since FY2021.
26 $14,832,351
Rank history: #32 in FY2021, #74 in FY2023, not on the FY2024 list and #42 in FY2025; up 6 since FY2021.
27 $13,436,467
Rank history: not on the FY2021 list, #13 in FY2023, #14 in FY2024 and #14 in FY2025; up 75 since FY2021.
28 $12,619,832
Rank history: not on the FY2021 list, #29 in FY2023, #24 in FY2024 and not on the FY2025 list; new.
29 $12,318,053
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
30 $12,000,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
31 $11,881,831
Rank history: #26 in FY2021, #16 in FY2023 and not on the FY2024–FY2025 lists; down 5 since FY2021.
32 $10,821,029
Rank history: #47 in FY2021 and not on the FY2023–FY2025 lists; up 15 since FY2021.
33 $7,987,925
Rank history: #75 in FY2021, #19 in FY2023, #27 in FY2024 and not on the FY2025 list; up 42 since FY2021.
34 $7,385,763
Rank history: #34 in FY2021, not on the FY2023 list, #20 in FY2024 and #65 in FY2025; unchanged since FY2021.
35 $7,098,773
Rank history: #24 in FY2021, #26 in FY2023, #26 in FY2024 and not on the FY2025 list; down 11 since FY2021.
36 $6,486,155
Rank history: #33 in FY2021, #15 in FY2023, #17 in FY2024 and not on the FY2025 list; down 3 since FY2021.
37 $6,415,198
Rank history: not on the FY2021 list, #56 in FY2023 and not on the FY2024–FY2025 lists; new.
38 $6,338,748
Rank history: #31 in FY2021, #18 in FY2023, #30 in FY2024 and #37 in FY2025; down 7 since FY2021.
39 $5,773,605
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 69 since FY2021.
40 $5,639,574
Rank history: #29 in FY2021, #38 in FY2023, #64 in FY2024 and #55 in FY2025; down 11 since FY2021.
41 $4,791,570
Rank history: #39 in FY2021, #23 in FY2023, #35 in FY2024 and #30 in FY2025; down 2 since FY2021.
42 $3,308,074
Rank history: #58 in FY2021, #34 in FY2023, #67 in FY2024 and not on the FY2025 list; up 16 since FY2021.
43 $3,135,290
Rank history: #56 in FY2021, #37 in FY2023, #53 in FY2024 and not on the FY2025 list; up 13 since FY2021.
44 $3,134,479
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 65 since FY2021.
45 $2,994,684
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #27 in FY2025; new.
46 $2,805,378
Rank history: #51 in FY2021, #46 in FY2023, #79 in FY2024 and not on the FY2025 list; up 5 since FY2021.
47 $2,555,913
Rank history: #40 in FY2021, #63 in FY2023, #47 in FY2024 and not on the FY2025 list; down 7 since FY2021.
48 $2,272,083
Rank history: #65 in FY2021, #32 in FY2023, #33 in FY2024 and #33 in FY2025; up 17 since FY2021.
49 $2,250,776
Rank history: #37 in FY2021, #30 in FY2023, #55 in FY2024 and #83 in FY2025; down 12 since FY2021.
50 $2,237,315
Rank history: #48 in FY2021, #70 in FY2023, #37 in FY2024 and #38 in FY2025; down 2 since FY2021.
51 $2,218,029
Rank history: #87 in FY2021, #88 in FY2023 and not on the FY2024–FY2025 lists; up 36 since FY2021.
52 $2,215,596
Rank history: #59 in FY2021, #40 in FY2023, #54 in FY2024 and #44 in FY2025; up 7 since FY2021.
53 $2,120,534
Rank history: #62 in FY2021, #36 in FY2023, #42 in FY2024 and not on the FY2025 list; up 9 since FY2021.
54 $2,096,964
Rank history: #91 in FY2021 and not on the FY2023–FY2025 lists; up 37 since FY2021.
55 $1,951,511
Rank history: #50 in FY2021, #27 in FY2023, #32 in FY2024 and #32 in FY2025; down 5 since FY2021.
56 $1,920,978
Rank history: #84 in FY2021, #39 in FY2023 and not on the FY2024–FY2025 lists; up 28 since FY2021.
57 $1,856,569
Rank history: #96 in FY2021, not on the FY2023 list, #84 in FY2024 and #95 in FY2025; up 39 since FY2021.
58
Cambridge Isotope Laboratories Inc. Through Otsuka America Pharmaceutical Inc.
$1,838,949
Rank history: #67 in FY2021, #67 in FY2023 and not on the FY2024–FY2025 lists; up 9 since FY2021.
59 $1,837,809
Rank history: #17 in FY2021 and not on the FY2023–FY2025 lists; down 42 since FY2021.
60 $1,805,425
Rank history: #97 in FY2021, #44 in FY2023, #97 in FY2024 and not on the FY2025 list; up 37 since FY2021.
61 $1,764,488
Rank history: #41 in FY2021, #25 in FY2023, #36 in FY2024 and not on the FY2025 list; down 20 since FY2021.
62 $1,638,197
Rank history: #35 in FY2021, #45 in FY2023, #83 in FY2024 and #52 in FY2025; down 27 since FY2021.
63 $1,585,032
Rank history: #49 in FY2021, #35 in FY2023, #46 in FY2024 and not on the FY2025 list; down 14 since FY2021.
64 $1,571,369
Rank history: #61 in FY2021, #42 in FY2023, #52 in FY2024 and #61 in FY2025; down 3 since FY2021.
65 $1,382,101
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
66 $1,351,509
Rank history: #60 in FY2021, #55 in FY2023, #61 in FY2024 and #54 in FY2025; down 6 since FY2021.
67 $1,333,766
Rank history: not on the FY2021 list, #61 in FY2023, #56 in FY2024 and #88 in FY2025; up 39 since FY2021.
68
Heritage Pharmaceuticals Inc.
$1,320,000
Rank history: #86 in FY2021 and not on the FY2023–FY2025 lists; up 18 since FY2021.
69 $1,316,678
Rank history: #80 in FY2021, #47 in FY2023, #50 in FY2024 and #97 in FY2025; up 11 since FY2021.
70 $1,297,622
Rank history: #70 in FY2021, #49 in FY2023, #43 in FY2024 and #75 in FY2025; unchanged since FY2021.
71 $1,287,280
Rank history: #52 in FY2021, #57 in FY2023, #70 in FY2024 and #35 in FY2025; down 19 since FY2021.
72 $1,238,139
Rank history: #71 in FY2021, #58 in FY2023, #93 in FY2024 and not on the FY2025 list; down 1 since FY2021.
73
AHS Hillcrest Medical Center LLC Through Topeka Hospital, LLC
$1,203,478
Rank history: not on the FY2021 list, #66 in FY2023 and not on the FY2024–FY2025 lists; up 82 since FY2021.
74 $1,198,134
Rank history: #53 in FY2021, not on the FY2023 list, #63 in FY2024 and #82 in FY2025; down 21 since FY2021.
75 $1,126,276
Rank history: #69 in FY2021, #54 in FY2023 and not on the FY2024–FY2025 lists; down 6 since FY2021.
76 $952,040
Rank history: not on the FY2021 list, not on the FY2023 list, #77 in FY2024 and not on the FY2025 list; new.
77 $948,203
Rank history: #68 in FY2021 and not on the FY2023–FY2025 lists; down 9 since FY2021.
78
Avista Pharma Solutions Inc.
$807,889
Rank history: #57 in FY2021 and not on the FY2023–FY2025 lists; down 21 since FY2021.
79 $787,516
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
80 $772,643
Rank history: #66 in FY2021 and not on the FY2023–FY2025 lists; down 14 since FY2021.
81
Recordati Rare Diseases,
$692,837
Rank history: not on the FY2021 list, #87 in FY2023, #91 in FY2024 and not on the FY2025 list; up 34 since FY2021.
82 $691,874
Rank history: #27 in FY2021 and not on the FY2023–FY2025 lists; down 55 since FY2021.
83 $686,380
Rank history: #83 in FY2021 and not on the FY2023–FY2025 lists; unchanged since FY2021.
84 $672,445
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 182 since FY2021.
85 $633,835
Rank history: #73 in FY2021 and not on the FY2023–FY2025 lists; down 12 since FY2021.
86 $627,359
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 94 since FY2021.
87 $621,836
Rank history: not on the FY2021 list, #53 in FY2023 and not on the FY2024–FY2025 lists; up 60 since FY2021.
88 $621,446
Rank history: not on the FY2021 list, #79 in FY2023, #94 in FY2024 and not on the FY2025 list; up 64 since FY2021.
89
Jazz Pharmaceuticals Inc.
$614,016
Rank history: not on the FY2021 list, #60 in FY2023, #48 in FY2024 and #49 in FY2025; new.
90 $600,000
Rank history: #93 in FY2021, #84 in FY2023 and not on the FY2024–FY2025 lists; up 3 since FY2021.
91 $599,690
Rank history: not on the FY2021 list, not on the FY2023 list, #66 in FY2024 and #59 in FY2025; up 29 since FY2021.
92 $585,022
Rank history: not on the FY2021 list, #41 in FY2023, #45 in FY2024 and not on the FY2025 list; up 58 since FY2021.
93 $583,392
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
94 $553,064
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 111 since FY2021.
95 $550,404
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 36 since FY2021.
96 $537,200
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
97 $530,364
Rank history: not on the FY2021 list, #62 in FY2023, #57 in FY2024 and not on the FY2025 list; up 66 since FY2021.
98 $525,983
Rank history: not on the FY2021 list, #97 in FY2023, not on the FY2024 list and #78 in FY2025; new.
99 $518,000
Rank history: not on the FY2021 list, #68 in FY2023, #39 in FY2024 and #45 in FY2025; new.
100
Luitpold Pharmaceuticals Inc. 2 awardees, including American Regent Inc.
$516,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 83 since FY2021.
Show 75 more

100 of 330 contractors listed here. See the rest on GovTribe.

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $35.2 billion obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Fiscal year 2022 ran Oct 1, 2021 – Sep 30, 2022. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
  • Rank changes compare with FY2021. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2021 takes the color of the rank change beside it.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 NAICS 325412 contractors in FY2022?

1. Pfizer Inc. ($14.6B), 2. Mckesson Corporation ($9.76B), 3. ELI Lilly and Company ($2.75B), 4. Modernatx Inc. ($1.85B), 5. Glaxosmithkline LLC ($1.64B), 6. Merck & Co. Inc. ($997M), 7. Quidel Corp ($605M), 8. Astrazeneca PLC ($576M), 9. Orasure Technologies Inc. ($400M), 10. Abbott Laboratories ($384M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work